Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 197, Issue 5, Pages 686-692Publisher
OXFORD UNIV PRESS INC
DOI: 10.1086/527328
Keywords
-
Categories
Funding
- NIAID NIH HHS [T32 AI07536, T32 AI007536-01] Funding Source: Medline
- PHS HHS [T01/CCT622892] Funding Source: Medline
Ask authors/readers for more resources
To address concerns that a flavivirus vaccine/wild-type recombinant virus might have a high mosquito infectivity phenotype, the yellow fever virus (YFV) 17D backbone of the ChimeriVax-dengue 4 virus was replaced with the corresponding gene sequences of the virulent YFV Asibi strain. Field-collected and laboratory-colonized Aedes aegypti mosquitoes were fed on blood containing each of the viruses under investigation and held for 14 days after infection. Infection and dissemination rates were based on antigen detection in titrated body or head triturates. Our data indicate that, even in the highly unlikely event of recombination or substantial backbone reversion, virulent sequences do not enhance the transmissibility of ChimeriVax viruses. In light of the low-level viremias that have been observed after vaccination in human volunteers coupled with low mosquito infectivity, it is predicted that the risk of mosquito infection and transmission of ChimeriVax vaccine recombinant/revertant viruses in nature is minimal.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available